CELZ - יחס חוב להיוון בספרים creativemedicaltechnology.com

Creative Medical Technology (CELZ) relies on outsourcing clinical tests to external laboratories while maintaining internal control over its technologies. The current debt-to-book capitalization ratio, as shown on the GURU.Markets chart, demonstrates a credit load where 0.00 determines this specific parameter level. Management is focused on patent protection and reporting transparency, which is critical amid extreme competition for leadership in regenerative medicine.

For Creative Medical Technology (CELZ), a cell therapy developer, the capital structure trend of debt-to-book capitalization reflects the balance between borrowed funds and equity. This metric compares total liabilities with the net asset value of the enterprise. A decrease in the ratio minimizes default risk but may limit the growth rate of regenerative research. The indicator's dynamics demonstrate the real financial stability of the biotech business, allowing investors to objectively assess the asset's debt load.